HB2346 - 104th General Assembly

 


 
HB2346 EnrolledLRB104 06540 BDA 16576 b

1    AN ACT concerning health.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Drug Reuse Opportunity Program Act
5is amended by changing Sections 5, 45, and 55 and by adding
6Section 70 as follows:
 
7    (410 ILCS 715/5)
8    Sec. 5. Definitions. In this Act:
9    "Controlled substance" means a drug, substance, or
10immediate precursor in Schedules I through V of 21 CFR 1308.
11    "Department" means the Illinois Department of Public
12Health.
13    "Dispense" has the same meaning as defined in Section 3 of
14the Pharmacy Practice Act.
15    "Donor" means any person, including an individual member
16of the public, or any entity legally authorized to possess
17medicine, including, but not limited to, a wholesaler or
18distributor, third party logistic provider, pharmacy,
19dispenser, clinic, surgical or health center, detention and
20rehabilitation center, jail, prison laboratory, medical or
21pharmacy school, prescriber or other health care professional,
22long-term care facility, or healthcare facility. "Donor"
23includes government agencies and entities that are federally

 

 

HB2346 Enrolled- 2 -LRB104 06540 BDA 16576 b

1authorized to possess medicine, including, but not limited to,
2drug manufacturers, repackagers, relabelers, outsourcing
3facilities, health care facilities operated by the U.S.
4Department of Veterans Affairs, and prisons.
5    "Drug" means a prescription drug, over-the-counter drug,
6or supplies needed to administer a prescription or
7over-the-counter drug.
8    "Eligible patient" means an individual:
9        (1) with a prescription for the drug, if a
10    prescription is required to dispense the drug, or who
11    reports symptoms treated by the drug if the drug is
12    over-the-counter; and
13        (2) who is registered with the drug's manufacturer in
14    accordance with federal Food and Drug Administration
15    requirements, if the registration is required to dispense
16    the drug.
17    "Manufacturer" has the same meaning as defined in Section
1815 of the Wholesale Drug Distribution Licensing Act.
19    "Pharmacist" means an individual licensed to engage in the
20practice of pharmacy under the Pharmacy Practice Act or
21licensed to engage in the practice of pharmacy in another
22state.
23    "Practitioner" means a person licensed in this State to
24dispense or administer drugs or who is licensed in another
25state as a person authorized to dispense or administer drugs.
26    "Prescription drug" means any prescribed drug that may be

 

 

HB2346 Enrolled- 3 -LRB104 06540 BDA 16576 b

1legally dispensed by a pharmacy. "Prescription drug" does not
2include a drug for the treatment of cancer that can only be
3dispensed to a patient registered with the drug manufacturer
4in accordance with the federal Food and Drug Administration's
5requirements.
6    "Priority patient" means an eligible patient who is an
7Illinois resident and who is indigent, uninsured,
8underinsured, or enrolled in a public health benefits program.
9    "Recipient" means any person or entity legally authorized
10to possess medicine with a license or permit in the state in
11which the person or entity is located, including, but not
12limited to, a wholesaler or distributor, reverse distributor,
13repackager, hospital, pharmacy, or clinic.
14    "Returns processor" has the same meaning as defined in
15paragraph (18) of 21 U.S.C. 360eee. "Returns processor"
16includes, but is not limited to, a reverse distributor.
17    "Unopened tamper-evident packaging" has the same meaning
18as defined in the United States Pharmacopeia (USP) General
19Chapter 659, Packaging and Storage Requirements, including,
20but not limited to, unopened unit-dose, multiple-dose,
21immediate, secondary, and tertiary packaging.
22(Source: P.A. 102-389, eff. 1-1-22.)
 
23    (410 ILCS 715/45)
24    Sec. 45. Recordkeeping requirements. When performing any
25action associated with a program under this Act or otherwise

 

 

HB2346 Enrolled- 4 -LRB104 06540 BDA 16576 b

1processing a donated drug for tax, manufacturer, or other
2credit, a recipient shall be considered to be acting as a
3returns processor and shall comply with all recordkeeping
4requirements for nonsalable nonsaleable returns under federal
5law. Records maintained under this Act may be accessed by the
6Department upon request.
7(Source: P.A. 102-389, eff. 1-1-22.)
 
8    (410 ILCS 715/55)
9    Sec. 55. Retention of records. All records required under
10this Act shall be retained in physical or electronic format
11and on or off the recipient's premises for a period of 6 years.
12Donors or recipients may contract with one another or a third
13party to create or maintain records on each other's behalf. An
14identifier, such as a serial number or bar code, may be used in
15place of any or all information required by a record or label
16pursuant to this Act if it allows for such information to be
17readily retrievable. Upon request by a State or federal
18regulatory agency, the identifier used for requested records
19shall be replaced with the original information. An identifier
20shall not be used on patient labels when dispensing or
21administering a drug. Records maintained under this Act may be
22accessed by the Department upon request.
23(Source: P.A. 102-389, eff. 1-1-22.)
 
24    (410 ILCS 715/70 new)

 

 

HB2346 Enrolled- 5 -LRB104 06540 BDA 16576 b

1    Sec. 70. Program support provided by the Department.
2    (a) The Department shall:
3        (1) develop, maintain, and publish on its website
4    information regarding the names and locations of
5    pharmacies participating in the Illinois Drug Reuse
6    Opportunity Program;
7        (2) educate pharmacies in the State about the Illinois
8    Drug Reuse Opportunity Program and how to participate in
9    it voluntarily;
10        (3) develop and publish educational materials to allow
11    program participants and the Department to inform the
12    general public about the purposes and benefits of the
13    program; and
14        (4) collect information from participants and publish
15    the information in an annual report to the General
16    Assembly by December 31 of each calendar year, beginning
17    December 31, 2026.
18    (b) Pharmacy recipients shall notify the Department of
19their participation in the dispensing of drugs under this Act
20and shall report any data required in a reasonable format
21established by the Department.